Assay Validation for KIM-1: human urinary renal dysfunction biomarker by Chaturvedi, Shalini et al.
Int. J. Biol. Sci. 2009, 5 
 
 
http://www.biolsci.org 
128
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2009; 5(2):128-134 
© Ivyspring International Publisher. All rights reserved 
Research Paper 
Assay Validation for KIM-1: human urinary renal dysfunction biomarker 
Shalini Chaturvedi, Takeisha Farmer, and Gordon F. Kapke 
 
Department of Biomarker Services, Covance Central Laboratory Services Inc., 8211 SciCor Drive, Indianapolis, Indiana 
46214-2985, USA   

 Correspondence to: Gordon F. Kapke, Ph.D., Tel.: 317-273-7901; Fax: 317-273-7990; E-mail: gordon.kapke@covance.com 
Received: 2008.10.17; Accepted: 2009.01.17; Published: 2009.01.19 
Abstract 
Urinary kidney injury molecule (KIM-1) is a sensitive quantitative biomarker for early detec-
tion of kidney tubular injury. The objective of the present work was to analytically validate 
this urinary renal injury biomarker. Duo-set reagents from R&D were used to develop the 
ELISA and validate the assay’s linearity, intra-run precision, inter-run precision, lower limit of 
quantification, recovery, dilutional verification, reference range, stability, and length of run. 
The reference range data suggests that the healthy population falls within the assay range (59 
- 2146 pg/mL) and upper limit of quantitation for this assay is 17168 pg/mL for the patient 
population. This is a robust assay to detect urinary levels of KIM-1, which serves as a 
non-invasive sensitive, reproducible, and potentially high-throughput method to detect early 
kidney injury in drug development studies. 
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Introduction 
Acute kidney injury (AKI) has been defined as a 
rapid decline in glomerular filtration rate that occurs 
over hours or days [1, 2]. AKI is common, and abso-
lute incidence of AKI has increased [3], diagnosis of 
which is frequently based on measurements of blood 
urea nitrogen (BUN) [4]. BUN and serum creatinine 
are not very specific or sensitive for the diagnosis of 
AKI because they are affected by many renal and 
non-renal (age, sex, race, muscle mass, nutritional 
status, infection, and volume of distribution, certain 
medications) [5-7] factors that are independent of 
kidney injury or kidney function.  
  Clearly, there is a need to identify a more spe-
cific AKI biomarker that is produced at the site of in-
jury, can be measured easily in blood or urine and 
s h o u l d  b e  r e a s o n a b l y  s t a b l e  i n  b o d y  f l u i d s  t o  s u b -
stantially improve the diagnosis. Several biomarkers 
have been studied in animal models and human of 
AKI [4], and kidney injury molecule-1 (KIM-1) is a 
recently discovered tubular protein that is markedly 
induced after ischemic reperfusion injury and in re-
sponse of a number of other proximal tubular toxins, 
such as cisplatin and folic acid [8, 9]. KIM-1 is a type I 
transmembrane glycoprotein, with an ectodomain 
containing Ig-like domain and a mucin domain [8]. It 
is undetectable in healthy kidney tissue, but ex-
pressed at very high levels in dedifferentiated proxi-
mal tubule epithelial cells in human and rodent kid-
neys after ischemic or toxic injury [8, 10].  
 Hence, KIM-1, the new biomarker of kidney in-
jury and glomerular filtration, holds the promise of 
substantially improving the diagnostic approach to 
acute kidney injury [9, 11]. Previously, an ELISA has 
been designed and validated for quantitating KIM-1 
in rat urine as an animal model, but this first genera-
tion ELISA has not been tested on human urine [12]. 
Subsequently, an ELISA has been developed previ-
ously to measure KIM-1 in human urine [13]. These 
KIM-1 reagents are not commercially available, 
therefore there is a need to develop, evaluate, and 
validate a high-throughput commercially available 
method for quantifying KIM-1 in human urine. Ana-Int. J. Biol. Sci. 2009, 5 
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lytically validating KIM-1 would provide clinical 
studies with the means to quantify the KIM-1 bio-
marker so that it can be evaluated for clinical practice. 
Therefore, the goal of the study was to analytically 
validate KIM-1 in human urine and demonstrate ap-
propriate clinical performance using the ELISA from a 
R&D duo-set [14]. 
This assay is a Sandwich ELISA based on: 1) 
uniformly coating goat anti-human KIM-1 in the mi-
cro-plate well, followed by washing and then block-
ing plates non-specifically, 2) binding of human 
KIM-1 in the sample to the immobilized KIM-1 anti-
body, 3) the binding of a biotinylated goat anti-human 
KIM-1 detection antibody, 4) wash away of unbound 
materials, followed by conjugation of strepta-
vidin-horseradish peroxidase to the immobilized 
biotinylated antibodies, 5) wash away of free enzyme, 
and 6) quantification of immobilized anti-
body-enzyme conjugates by monitoring horseradish 
peroxidase activities in the presence of the substrate 
3,3’,5,5’-tetra-methylbenzidine. The enzyme activity is 
measured spectrophotometrically by increased ab-
sorbance at 450 nm, corrected from the absorbance at 
540 nm, after acidification of formed products. Since 
the increase in absorbance is directly proportional to 
the amount of captured KIM-1 in the unknown sam-
ple, the concentration of KIM-1 can be derived by 
interpolation from a reference curve generated in the 
same assay with reference standards of known con-
centrations of human KIM-1 [14]. The standard curve 
concentrations used for all the KIM-1 ELISAs were 
2000, 1000, 500, 250, 125, 62.5, and 31.25 pg/mL and 
the absorbances read approximately 2.5, 1.5, 0.9, 0.5, 
0.25, 0.12, and 0.05 respectively. The curve fit for the 
analysis of the standard curve was four parametric 
logistic (4PL).   
Materials and Methods 
Sample collection from Healthy population: For the 
determination of the reference interval, blood and 
urine samples were collected from healthy healthcare 
professionals (10 males and 10 females). Individuals 
were informed of the testing to be performed and only 
the specified testing was performed on the collected 
reference specimens. Analyses were conducted with 
the full respect for the individual’s right to confiden-
tiality. Information regarding their age, gender and 
race was also collected with the healthcare profes-
sional’s consent to calculate the glomerular filtration 
rate (GFR). Urine creatinine and serum creatinine was 
assayed for each of these samples. Freshly collected 
urine samples were allowed to sit at room tempera-
ture for 30 minutes to sediment, and the supernatant 
was aliquoted and stored at –70 oC until analysis.   
Construction of KIM-1 sandwich ELISA (R&D Cat# 
DY1750, Minneapolis, MN): The wells of 
Nunc-Maxisorp EIA plates were coated by diluting 
the capture antibody (72 μg/mL) to a working con-
centration of 0.4 μg/mL in PBS with 100 μL in each 
well. The plate was sealed and incubated overnight at 
room temperature. Each well was aspirated and 
washed using an automated microplate washer 
(Bio-Tek) with 400 μL of Wash Buffer (0.05% 
Tween-20 in PBS), repeating the process two times for 
a total of three washes. The plates were blocked by 
adding 300 μL of reagent diluent (1% BSA in PBS, 0.2 
μm filtered) to each well and incubated at room tem-
perature for 2 hours. After washing as in the previous 
step, 100 µL of standard recombinant human KIM-1 
(0-2000 pg/mL), control, and urine sample was pi-
petted to the designated well, covered with an adhe-
sive strip, and placed on the orbital shaker at 400 rpm 
at room temperature for 2 hours. The plate was 
washed using the same wash protocol as before, and 
100  μL of the biotinylated goat anti-human KIM-1 
detection antibody diluted in reagent diluent to a 
working concentration of 400 ng/mL was added to 
each well. The plate was covered with a new adhesive 
strip, incubated at room temperature for 2 hours with 
continued shaking at 400 rpm. Washing step was re-
peated and 100 μL of streptavidin-HRP diluted to a 
working dilution was added to each well. The plate 
was protected from light, covered with a new adhe-
sive strip, shaken at 400 rpm, and incubated at room 
temperature for 20 minutes. After washing, 100 µL 
substrate solution was added to all wells, protected 
from light, covered with an adhesive strip, shaken at 
400 rpm, and incubated at room temperature for 7 
minutes. The reaction was stopped by adding 50 µL of 
stop solution to all wells. The absorbance was meas-
ured using a plate reader (BioTek Elx800) at 450 nm 
with an absorbance correction at 540 nm. The urinary 
KIM-1 concentration was calculated based on the 
standard curve and expressed in absolute terms 
(pg/mL). 
Evaluation of the KIM-1 ELISA: The validation of 
the KIM-1 ELISA was evaluated by measuring linear-
ity, intra-run precision, inter-run precision, analytical 
sensitivity, recovery, dilution verification, reference 
range, stability and length of run. Details of the crite-
ria for each are described in the result section.  
Sample collection and analysis: Urine samples were 
collected asceptically directly in urine cups and stored 
at –70 oC within 4 hours. All statistical analysis was 
carried out using the program EP evaluator [15] (ver-
sion 8.0, DG Rhoads). 
Analytical Testing: Urinary creatinine was meas-
ured by the Jaffe rate-blanked creatinine assay using a Int. J. Biol. Sci. 2009, 5 
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Roche/ Hitachi 911 system (Roche Diagnostics, Indi-
anapolis, IN, USA). Serum enzymatic creatinine was 
measured using the Roche/Hitachi P800 analyzer. 
Glomerular filteration rate (GFR) was calculated us-
ing the MDRD (modification of diet in renal disease) 
formula 186 X (SerumCreatinine)-1.154 X (Age)-0.203 X (0.742 
if female and 1.000 if male) X (1.210 if African 
American and 1.000 if others) (mL/min/1.73m2) [16]. 
Results 
Linearity: In order to know the range of the assay, 
it is important to define the linear range of the assay. 
To define the range, a high standard was serially di-
luted with reagent diluent to give a series of speci-
mens (100 + 0, 75 + 25, 50 + 50, 25 + 75, and 0 + 100). 
Each sample was assayed for KIM-1 in duplicates (N 
= 4), and slope calculated. The plotted linearity shows 
a slope of 1.051, and the data demonstrates that the 
assay is acceptably linear to 2146 pg/mL (Figure 1).  
 
 
Figure 1: Linearity: KIM-1 linearity was demonstrated with 
the high standard diluted proportionately with buffer.  
Precision: Two sets (low and high) of pooled 
urine samples were created and each set was run on 
two separate plates for N=20, % CV calculated for 
each to give intra-low and intra-high precision. The 
intra-low sample gave an average reading of 170 ± 11 
pg/mL (CV = 6.4 %, N = 20), while the intra-high 
sample averaged 2007 ± 98 pg/mL (CV = 4.9 %, N = 
20). Low and high pools were also run on 8 separate 
plates, and % CV calculated to give an inter-low and 
inter-high precision (Table 1). The mean low value for 
inter-low precision was 164 ± 10 pg/mL (CV = 6.0 %, 
N = 8), and that of inter-high precision was 383 ± 15 
pg/mL (CV = 3.8 %, N = 8). 
Table 1: KIM-1 assay precision 
 
 
 
Sensitivity: The assay’s lower limit of quantifica-
tion (LLOQ) is defined as the lowest concentration at 
which an across run %CV can be generated that is less 
than 20%. A series of samples in the concentration 
range of 57 to 384 pg/mL were generated to provide 
multiple low samples that were aliquoted and frozen. 
Samples were thawed and analyzed on 10 separate 
plates over several days. The %CV of each sample was 
determined from the 10 analytical runs and the lowest 
sample that demonstrated inter-assay precision 
(%CV) of less than 20% was the LLOQ of the assay. 
The LLOQ for the assay as read from the curve is de-
fined as 59 pg/mL (%CV = 19.8).  
Recovery: In order to establish the % recovery, 5 
urine samples were identified that read between 120 – 
550 pg/mL and one high sample that read 1805 
pg/mL. A second set of 5 samples were generated by 
mixing 10 % of the high sample with 90 % of the low 
samples. These samples were then assayed for KIM-1 
activity. Based on the observed concentration of 
KIM-1 for the original 5 samples, the expected values 
were calculated. The average recovery of the samples 
was found to be 89.4 % (Table 2). 
 
Table 2: KIM-1 recovery; where 1:10 represents a mixture 
of 90% of sample and 10% of spike. The expected value was 
compared with the observed value and recovery calculated. 
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Dilution Verification: The dynamic range for the 
measurement of KIM-1 has been defined as 59 – 2146 
pg/mL. This range poses difficulty for samples that 
are higher than the defined range. The problem is 
typically resolved by diluting the sample so that the 
reading falls within the defined range. The reading is 
then multiplied with the dilution factor to generate 
the true value. This is valid only if the dilution process 
is linear. A high sample (694.40 pg/mL) was diluted 
1:2, 1:4, 1:8, 1:16, 1:32, and 1:64 in reagent diluent and 
each diluted reading was assayed for % recovery. The 
high sample diluted appropriately to 1:8, with 87.0 % 
recovery, demonstrating that the high sample can be 
diluted at least 8 fold, indicating the upper limit of 
quantification (upper limit of quantification = upper 
limit of linearity X highest dilution allowed) to be 
17168 pg/mL (2146 X 8) (Figure 2).  
Reference Range: Urine and serum was collected 
from 20 healthy donors (10 males and 10 females), 
assayed for urinary KIM-1, urinary creatinine and 
serum creatinine. KIM-1 ranged from 60 – 837 pg/mL, 
and when normalized to urinary creatinine, the re-
sults spanned the range of 0.070 – 0.399 
KIM-1(ng)/Urinecreatinine(mg), with one outlier at 0.988 
(Figure 3). The MDRD calculated GFR for all the 
volunteers was > 65.00 (Table 3).  
 
 Figure 2: Dilution Verification: A urine specimen with a 
high endogenous KIM-1 concentration was serially diluted 
with reagent diluent, assayed and % recovery calculated. 
Most diluted samples recovered between 80 – 120 % of 
expected concentration.  
Table 3: Summary of baseline characteristics of healthy population.  
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Figure 3: Reference Interval: Urine specimens collected from 20 healthy subjects was assayed to determine the reference 
range of KIM-1. Values for healthy volunteers ranged from 60 – 837 pg/mL, and the ratios 
KIM-1(ng/mL)/UrineCreatinine(mg/mL) ranged from 0.070 – 0.399, with one outlier at 0.988. 
Length of run: In order to make sure that there was no plate effect, and the samples read the same on any 
well in the plate, we placed QC samples at the end of lanes 6, 9 and 12. The SD calculated during the intra-run 
precision was 11 pg/mL (CV = 6.4%) for intra-low, and 98 pg/mL (CV = 4.9%) for intra-high. The 3 SD range 
was established and applied to the QC samples on the plate. The range was calculated to be 142 – 210 pg/mL for 
the low and 350 – 471 pg/mL for the high QC samples. QC samples in lanes 6, 9, and 12 fell within range con-
firming the length of run experiment.  
Stability: To test the stability of the samples over time, freeze-thaw cycles, and storage temperatures (room 
temperature, 4, -20, -70 oC), aliquoted samples (N=6) in 21 different tubes were subjected to a host of conditions. 
The % recovery was compared to the baseline value for all 6 samples. KIM-1 was found to be stable up to 7 days 
refrigerated and ambient conditions. Samples recovered within 99-114 % when subjected to 3 freeze-thaw cycles, 
and also at –20 oC, and –70 oC at 14 days (Figure 4). Stability studies up to 1 year are under way.  
 
 
Figure 4: Stability: Recovery of KIM-1 at ambient, refrigerated, –20, and –70 
oC over 14 days; and 2 and 3 times freeze-thaw 
was compared to the baseline samples (N = 6). The plotted data is the mean value for the 6 samples. The mean value for 
sample 1-6 across different conditions is 56.44 ± 33.22, 253.43 ± 37.43, 668.62 ± 199.19, 315.29 ± 35.15, 396.76 ± 77.61, 
401.66 ± 51.63 pg/mL. Sample 1 reading 56.44 is below the LLOQ, therefore a high standard deviation is not unusual. Int. J. Biol. Sci. 2009, 5 
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Discussion 
The US FDA and European Medicines Agency 
(EMEA) have completed a major milestone under 
their Critical Path and Roadmap to 2010 through an 
extensive process of data generation and analysis and 
“qualified” seven new nephrotoxicity biomarkers for 
use in regulatory decision-making. This consortium of 
public-private partnership led by the Critical Path 
Institute, generated and submitted the data for seven 
urinary proteins- KIM-1, albumin, total protein, 
β2-microglobulin, cystatin C, clusterin, and trefoil 
factor-3. Efforts are underway to qualify these mark-
ers for human studies and clinical trials [17, 18]. The 
evaluated product is the only commercially available 
KIM-1 assay to support broad use of this newly rec-
ognized regulatory biomarker. 
There is a growing body of evidence that sup-
ports KIM-1 as a specific marker for ischemic renal 
injury, and therefore a sensitive, validated assay to 
measure urinary levels of KIM-1 is required for clini-
cal research. A rigorous validation of the KIM-1 assay 
to optimize the performance for high-throughput 
routine clinical research was performed. The com-
mercially available KIM-1 assay described in this pa-
per is suitable to assay KIM-1 in human urine.  
This paper reports development of a commer-
cially available quantitative assay for measuring 
KIM-1 in human urine. This assay could have direct 
implications for evaluation of nephrotoxicity in hu-
m a n s  w h e r e  r e l i a n c e  o n  s e rum creatinine is ques-
tioned. A significant advantage of this KIM-1 assay is 
the ease of use, analytical sensitivity, and rapid 
throughput, making the assay reliable for diagnostic 
and prognostic measurements. All the solutions are 
prepared easily using commercially available buffers 
and the recombinant KIM-1 protein was used as the 
assay standard. The KIM-1 assay has dynamic range 
of 0-2146 pg/mL and a lower limit of quantification of 
59.0 pg/mL with inter-assay variability of 19.8 %. The 
performance characteristics of the ELISA are consis-
tent over time, making it a robust assay for research 
and clinical research use. This study, for the first time, 
gives us data on the short-term stability of the KIM-1. 
The long-term stability data is being generated as 
well. The experiment on dilution verification show 
appropriate recovery up to a 1:8 dilution, indicating 
no interference in the urine matrix from any other 
factors. This is further confirmed by the spike recov-
ery results giving approximately 90 % recovery.  
The only other human KIM-1 data has been 
published by Han et. al [10]. Their normalized KIM-1 
levels in normal healthy individuals were less than 
those of other acute renal failure patients at 0.48 ± 0.19 
(ng)/Urinecreatinine(mg). The exact normal values were 
not published. The determined reference range (mean 
± 2SD) in our lab with 19 donors (one outlier re-
moved) was 0.228 ± 0.188 (ng)/Urinecreatinine(mg), and 
including the outlier was 0.266 ± 0.386 
(ng)/Urinecreatinine(mg). The value of 0.988 
(ng)/Urinecreatinine(mg) was well above the 3SD range, 
which is why it was considered an outlier.  
Investigators in the past have relied on multiple 
classical laboratory tests to detect AKI, but the biggest 
disadvantage these tests have is time delay between 
injury and detection making them marginally effec-
tive biomarkers. Some of the disadvantages current 
biomarkers face are: lack of stability, lack of stability 
due to pH of urine which means the analyte has to be 
neutralized soon after collection, need to add stabi-
lizers soon after collection, inhibition due to metals, 
lack of specificity, and onset of elevation and sus-
tainability. KIM-1 has excellent frozen stability and 
the literature indicates excellent sensitivity to AKI. 
The KIM-1 ELISA assay also provides the throughput 
to handle large number of samples over extended 
period of time.  
In conclusion, analytical validation of the KIM-1 
assay demonstrates this assay can be used reliably 
and routinely in a standard clinical research setting. 
The analytical performance of this assay permits 
meaningful comparison of data between trials. KIM-1 
has a great potential as a biomarker of renal injury, 
and the R&D duo set assay provides the ability for 
any researcher to generate KIM-1 data.  
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